• Product NameRecombinant Human 4-1BB Ligand/TNFSF9
• Host SpeciesE.coli
• Purification> 95 % by SDS-PAGE and HPLC analyses.
• Biological ActivityFully biologically active when compared to standard. The ED50 as determined by stimulation of IL-8 production using human PBMC is less than 10 ng/ml, corresponding to a specific activity of > 1.0 �� 10⁵ IU/mg.
• EndotoxinLess than 1 EU/ug of rHu4-1BBL as determined by LAL method.
• Alternative Names    TNFSF9, CD137L
• UniprotP41273
• Gene ID8744
• Calculated MW Approximately 19.4 kDa, a single non-glycosylated polypeptide chain containing 184 amino acids.
• Target Sequence REGPELSPDD PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE
• Formulation Lyophilized from a 0.2 um filtered concentrated solution in PBS.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70˚C under sterile conditions after reconstitution.

4-1BBL is a member of the tumor necrosis factor (TNF) receptor family. This receptor contributes to the clonal expansion, survival, and development of T cells. In addition, 4-1BBL expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. CD137 has been shown to interact with TRAF2. The human 4-1BBL gene codes for a 254 amino acid type II transmembrane containing a 28 amino acid cytoplasmic domain, a 21 amino acid transmembrane domain, and a 205 amino acid extracellular domain (ECD). The human 4­1BBL ECD shares 32 % and 35 % a.a. identity with murine and rat ECD.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting